Vandetanib almost doubles progression free survival in patients with thyroid cancer

August 13, 2012

Results of a phase 2 randomised trial for patients with advanced differentiated thyroid cancer (DTC) show that those treated with the oral targeted agent vandetanib survived without the disease getting worse for almost twice as long as patients given placebo (11.1 months vs 5.9 months). The findings, published Online First in The Lancet Oncology, are the first to show clear evidence of prolonged progression free survival (PFS) with a targeted agent for advanced DTC, a disease for which no effective treatment exists.

Over the past decade, the incidence of has more than doubled worldwide. Recently, multi-targeted have emerged as promising treatments for DTC, but until now, no placebo-controlled studies have been done.

Here, Martin Schlumberger from the Institut Gustave Roussy in France and colleagues aimed to establish whether vandetanib, a drug that targets three proteins known to play a key role in the growth and spread of thyroid cancer—endothelial growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and RET (REarranged during Transfection) protooncogene—would impact PFS and overall survival (OS).

The study randomly assigned 145 late-stage or advanced DTC patients from seven European countries to either 300 mg/day of vandetanib (72 patients) or placebo (73).

Compared with placebo, vandetanib was associated with significantly improved PFS of 11.1 months compared with 5.9 months. At 6 months, patients treated with vandetanib also had a significantly better disease control rate (DCR; which includes complete and partial responses and stable disease) than those given placebo. However, no significant difference in OS was noted between the groups.

Interestingly, patients with the more common papillary cancer (PTC) experienced more prolonged PFS (median PFS 16.2 months) than patients with either FTC or differentiated carcinoma (median PFS 7.7 months).

Patients who received vandetanib experienced much greater toxicities, in particular increased QTc prolongation (the lengthening of a specific interval of time in the heart's electrical cycle that can lead to death), diarrhoea, asthenia (weakness), and fatigue. Two treatment-related deaths also occurred in the vandetanib group.

According to Schlumberger, "These results are potentially good news for patients with aggressive DTC who currently have few treatment options. The significant improvements in PFS and DCR versus suggest that vandetanib may be an effective treatment option for long-term stabilization of advanced DTC, particularly for patients with PTC."

In a linked Comment, Keith Bible from the Mayo Clinic, Rochester, USA says, "Despite providing important additional evidence about the clinical activity of vandetanib in DTC, [the study] leaves the important issue of the effect of vandetanib on overall survival unresolved."

He adds, "More work is needed to better clarify which patients with DTC might have the greatest net benefits from kinase inhibitors…and to develop individualised treatment approaches in DTC."

Explore further: Vandetanib doesn't up survival in non-small-cell lung cancer

More information: Paper online: www.thelancet.com/journals/lan … (12)70335-2/abstract

Related Stories

Vandetanib doesn't up survival in non-small-cell lung cancer

March 2, 2012
(HealthDay) -- Vandetanib does not improve overall survival for patients who have received previous treatment for advanced non-small-cell lung cancer (NSCLC), according to a study published online Feb. 27 in the Journal of ...

Targeted therapy with pazopanib prolongs progression-free survival in advanced soft-tissue sarcoma

May 15, 2012
For patients with metastatic soft-tissue sarcoma whose disease has progressed following standard chemotherapy, treatment with pazopanib (a drug that targets the growth of new cancer-related blood vessels) nearly tripled progression-free ...

Recommended for you

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.